Dual Source CT System
The Somatom Force computed tomography (CT) system is the next generation in dual source CT. With two sets of Siemens Healthcare’s most innovative X-ray tubes and detectors, the Somatom Force extends advanced imaging to all patients, including some of the most challenging: young children, patients with renal insufficiency and patients who are unable to hold their breath. The Somatom Force overcomes imaging limitations, making low-dose CT available for an even broader array of patients. With the power reserves of its Vectron tube, the Somatom Force delivers routine adult imaging with fast, low-dose protocols.
Due to its low kV imaging, the Somatom Force broadens CT’s application for patients with renal insufficiency. While necessary for conventional CT imaging, iodine contrast medium can place a burden on the kidneys, especially for older patients or those with chronic kidney disease. Previously, clinicians had two options: scan without contrast or avoid scanning entirely. The Somatom Force extends CT’s use for these patients, especially in urgent situations when they can most benefit.
The Somatom Force enables the user to perform an entire adult chest, abdomen and pelvis study in only one second, so patients need not hold their breath. For example, patients who present with shortness of breath and are evaluated for pulmonary embolism can now be imaged with no breath hold, thanks to the Somatom Force’s Turbo Flash Mode. With no need for a patient breath hold, the healthcare organization can make faster, more confident decisions and can better deliver timely intervention. In cardiac imaging, the Somatom Force can obtain an entire study within a quarter of a heartbeat at a native temporal resolution of 66 ms — the speed required to freeze even the fastest-moving anatomy such as the right coronary artery.
The Somatom Force also may enable low-dose imaging in lung and colon exams. Low-dose imaging is attributable to two spectral filters known as Selective Photon Shields that optimize the X-ray spectrum to significantly improve air/soft-tissue contrast. Patients who are diagnosed with lung or colon cancer are likely to undergo additional follow-up imaging studies that can now be delivered at a continually low dose to enable more decisive treatment and post-therapy evaluations.
The system received FDA approval in April 2014.
For more information: www.siemens.com/healthcare